Shares of Aclarion Inc (NASDAQ:ACON) jumped 43.7% in premarket trading on Thursday after the healthcare technology company reported a strong acceleration in scan volumes for its Nociscan platform, which is designed to help physicians pinpoint the source of chronic low back pain.
The company said Nociscan scan volumes climbed 114% year over year in the fourth quarter of 2025, marking the third straight quarter of annual growth across sites in the United States, the United Kingdom and the European Union. For the full year, total scan volumes increased 69% compared with 2024.
As part of its commercial expansion, Aclarion added nine new imaging centers and signed up 22 additional physician users during 2025, strengthening its presence in key U.K. and U.S. healthcare markets.
Aclarion ended 2025 with a solid balance sheet, reporting $12.0 million in cash and no outstanding debt as of December 31. During the year, the company raised more than $22.0 million through equity financing, which management said extends its cash runway into 2027.
Looking ahead to 2026, Aclarion plans to enroll roughly 25% of patients in its CLARITY clinical trial by the end of the second quarter, with an initial internal review of interim data expected in the third quarter. The company also aims to broaden access to major MRI manufacturers, a move that would expand its available global market by more than 30%.
Nociscan uses biomarkers combined with proprietary augmented intelligence algorithms to assist physicians in identifying the underlying cause of chronic low back pain. In 2025, Aclarion also bolstered its intellectual property portfolio with four newly issued patents, bringing its total worldwide patent count to 52.